Clinical Trial

HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 6, 2024 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a single-arm exploratory clinical study to evaluate the efficacy and safety of HAIC in combination with Sintilimab and Donafenib in patients with BCLC-C stage who have not received prior systemic therapy
Trial Details
NCT Number NCT06244225
Lead Sponsor Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Conditions Hepatocellular Carcinoma
Enrollment 38 participants
Start Date 2024-01-01
Primary Completion 2026-01-01 (estimated)
Study Completion 2028-01-01 (estimated)
Updated on ClinicalTrials.gov 2024-02-06